-
Posted by
Two Blokes Apr 17 -
Filed in
Stock
-
2 views
Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and patent protections, making Pfizer's development pipeline crucial for long-term growth. Despite recent setbacks, Pfizer's strategic initiatives, including cost-cutting and acquisitions, position it for future profitability and market leadership.
